| INTRODUCTION
Androgenic anabolic steroids are modified androgens or prohormones that promote muscle growth and are used to enhance athletic performance or improve physique.
1,2 Several anabolic steroids have been approved as therapy of hypogonadism, cachexia, anaemia and other disorders. However, these products can also cause diverse liver abnormalities, including severe and prolonged cholestatic liver injury, peliosis hepatis, hepatic adenoma and even hepatocellular carcinoma with prolonged use, albeit in a minority of patients. [3] [4] [5] [6] [7] These risks, as well as cardiovascular injury, hyperlipidaemia, and infertility, along with the development of dependence, have prompted increasing Food and Drug Administration and Drug Enforcement Administration (DEA) regulation of anabolic steroids in the United States.
Despite the increased oversight, numerous examples of contamination of bodybuilding supplements with illegal anabolic steroids have been reported, demonstrating that these supplements remain an important source of illicit anabolic steroid exposure. 3, [8] [9] [10] Little is known about the pathophysiological mechanisms of prolonged cholestasis associated with anabolic steroids or who is at risk for developing liver injury. Previous small studies have identified a few variants associated with genetic cholestatic disorders in those that develop cholestastic liver injury after using bodybuilding supplements. 11, 12 Anabolic steroid modifications allowing for oral administration and those specifically with a C-17 alkylated modification are known to be associated with cholestatic liver injury, 1 but a detailed time course of liver injury, histologic evaluation, genetic characterisation and chemical analysis of supplements in a large cohort is lacking.
The drug-induced liver injury network (DILIN) has prospectively enrolled patients with drug or herbal and dietary supplement-associated liver injury to characterise their clinical features and to generate a well-phenotyped biospecimen repository for future mechanistic and genetic association studies. 13, 14 A previous review of the DILIN's experience with herbal and dietary supplement, which constituted the second most common class of agents causing drug-induced liver injury (DILI), identified supplements advertised to promote bodybuilding as the largest class within this category. 15 cases, respectively, to explore potential exposure to anabolic steroids and mechanisms of liver injury.
| MATERIALS AND METHODS

| Recruitment of DILIN prospective study
All patients were enrolled into an ongoing, multicentre prospective attributed to bodybuilding supplements. For the study, liver injury onset was defined as the first day of documented liver injury after being exposed to the bodybuilding supplement and meeting one of the following criteria for inclusion into the study on two successive blood samples, collected at least 24 h apart: (a) a serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level greater than five times the upper limit of normal (or five times the baseline elevated value if known); (b) a serum alkaline phosphatase (Alk Phos) level that exceeded two times the Upper limit of normal (ULN; or two times a pretreated abnormal baseline value if known);
or (c) a serum total bilirubin of 2.5 mg/dL or greater or an international normalised ratio (INR) greater than 1.5 in combination with any enzyme elevation. Patients with injury within the past 6 months were eligible for enrolment into the prospective study. A detailed review of the patient's medical history and record was performed at initial enrolment, and narrative generated summarising key clinical features. Additional laboratory tests and imaging studies were performed to exclude other potential aetiologies. In addition, patients were screened for hepatitis A, B, C, E, HIV, CMV and EBV infections and for routine autoantibodies. Patients were asked to return for follow-up at 6 months, and if evidence of persistent liver injury was noted at that time, they were asked to return for further follow-up at 12 and 24 months.
The assessment of causality between the liver injury and the implicated agent was carried out using a standardised process based upon the pertinent clinical, biochemical, radiological and histologic findings if available after the 6-month follow-up visit. 16 
| Duration of injury and pattern of hepatic injury
Jaundice was typically prolonged, the median time from onset to serum bilirubin falling below 2.5 mg/dL being slightly more than 3 months (94 days). Typically, serum aminotransferase levels fell rapidly during the course of the disease, the peak median ALT value (189 U/L) being minimally higher than the median value on Percentage of chronic patients at 6 mo followed up at 12 and 24 mo.
presentation (169 U/L). In contrast, serum Alk Phos levels typically rose, the peak median value being twice that of the initial value (257 vs 111 U/L). For these reasons, the R value fell rapidly during the course of the injury to a median of less than 2 (cholestatic) within 2 weeks. Figure 1 
| Liver histology
Twenty-six patients underwent liver biopsies, of which 22 were available for independent review by the DILIN hepatic pathologist (DEK), who was masked to all clinical information. The median time from DILI onset to the liver biopsy was 15 days (range 1-68). The most common histologic pattern was a mixed hepatocellular and cholestatic injury (77%), and only 4 (18%) had acute cholestasis.
Hepatocellular injury was typically spotty and mild, and no patient had bridging or confluent necrosis. Some degree of cholestasis was found in all biopsies but bile duct injury was found in only 14% without any bile duct loss. Steatosis was uncommon (10%), and no patient had more than mild portal fibrosis. One case showed microscopic evidence suggestive of peliosis hepatis and nodular regeneration. Only six anabolic steroids listed on the label were confirmed by chemical analysis. The anabolic steroids that were most frequently encountered were methyldrostanolone (55%) followed by tetrahydrocorticosterone (44%), 4-androstenedione (33%) and DHEA (33%). Table S1 are the case numbers, names of the primary bodybuilding supplements suspected to be the cause of the liver injury, whether the product label listed an anabolic steroid as an ingredient and, in 14 samples (nine subjects), whether an anabolic steroid was identified analytically. In some cases, none of the products contained detectable anabolic steroids or the product believed to contain one was not available for testing. Thirteen of the steroids identified were DEA controlled substances.
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| Genetic association studies
Twenty-five patients underwent WGS. Among the 22 patients of European-American ethnicity who underwent WGS, four were heterozygous (carriers) for rare missense variants in candidate genes previously reported to be associated with progressive familial intrahepatic cholestasis (PFIC) disorders: ATP8B1 (PFIC1), ABCB11 (BSEP) (PFIC2) or ABCB4 (MDR3) (PFIC3) ( Table 3) . Three additional patients, identified by exomic chip analysis, had variants in ATP8B1:
two carried the D70N missense variant associated with PFIC/BRIC1 cases, which also showed some evidence of enrichment in our cases To asses for overall enrichment of rare functional variants in these three genes in cases as compared to population controls, data from the gnomAD database were used to conservatively estimate that 12.3% of European ancestry population controls have a coding variant with a MAF below 1% in at least one of these genes, as compared to 20.6% in our cases. As 12 of our European ancestry cases were genotyped only for low-frequency coding variants by chip analysis (for included variants, see Table S2 ), some very rare variants may have been missed, but the frequency overall of cases with rare missense mutations in at least one of these genes was similar between our WGS cases (18%) and our exome chip cases (25%).
When variants were removed as predicted by PolyPhen-2 HumDiv 22 to be benign, only 8.1% of the population controls were predicted to be carriers, whereas 17.6% of cases remained carriers. Almost 9% of our European ancestry cases had rare missense variants predicted to be probably damaging in ATP8B1 as compared to 4.3% of controls (8.9% vs 5.6% when including benign variants), 5.8% in ABCB11 compared to 1.0% in controls (8.9% vs 3.3% with benign) and 2.9%
in ABCB4 compared to 2.7% in controls (2.9% vs 3.4% with benign).
In the bodybuilding supplement cases, there was some clustering of variants in specific regions of ABCB11 gene as compared to controls.
The two ABCB11 variants found in European ancestry cases, one of which was seen in two cases, were both in the ABC transmembrane domain. In contrast, no more than 0.4% of European ancestry gnomAD controls have rare missense variants in this region. Similarly, the two ATP8B1 variants found in our cases, one of which was seen in two cases, were within 25 amino acids of each other; in contrast, no more than 2.5% of controls have rare missense variants within 25 amino acids of either of these variants ( Figure S1 ). These findings suggest that genetic variants, particularly in ABCB11, might predispose to bodybuilding supplement-associated cholestatic injury in some individuals, as has been postulated for cholestasis due to pharmaceutical agents. 
| Clinical features of cholestatic liver injury due to anabolic steroids
The clinical features of cholestatic liver injury in these 44 patients are consistent with prior observations of those exposed to anabolic steroids that include C-17 alpha alkylation. 3, 24 The next largest case series describes 25 cases of anabolic steroid-associated liver injury, predominately attributed to stanozolol. 25 Other clinical descriptions consist of small case series with predominately oral agents. However, our study includes prospective data providing more detailed clinical course description and extensive genetic analysis in a majority of cases along with chemical analysis of bodybuilding supplements ingested, the latter carrying important regulatory implications.
All of our cases arose in men, typically young with few other medical problems. The vast majority admitted to drinking some alcohol in the past year, and we previously reported that heavy alcohol consumption was associated with exposure to bodybuilding supplements. 19 As compared to the subjects with bodybuilding supplement-associated DILI, the entire cohort of subjects enrolled into the DILIN with causality score of probably or greater, reported that only 50% had some alcohol consumption in the past year and of those that completed the alcohol survey, less than 23% were heavy drinkers as previously defined. 19 Subjects with bodybuilding Luteinizing hormone serum levels, changes in the epi-testosterone to testosterone ratio or in the C 13 /C 12 ratio of androgenic steroids in the urine. 29, 30 With regard to renal insufficiency (as defined by serum creatinine >1.5 mg/dL), only six patients were affected and of these, only three had creatinine persistently elevated above 2.5 mg/dL. The mechanism for renal injury during severe and prolonged cholestasis is unknown, but the anabolic steroid methasteron has been previously reported to be associated with renal injury, suggesting that renal injury may be associated with a specific chemical structure of the anabolic steroid. 31 Alternatively, elevated serum bile salts have also been implicated in causing renal injury. 32 Fortunately, none of the patients died or required liver transplantation. However, 16% of the patients were treated with a trial of corticosteroids, with little or no apparent clinical response, although this was not formally assessed.
In addition, almost half were enrolled on Ursodiol therapy, presumably for cholestatic symptoms. Follow-up was difficult with these patients as only 36% returned for a 6-month follow-up, a rate far lower than the average patient enrolled in DILIN (80%), probably reflecting the background good health of these patients and the illicit nature of the bodybuilding supplement use. None developed chronic cholestatic liver injury, vanishing bile duct syndrome 33 or liver failure requiring liver transplantation. There was eventual resolution of all liver tests in those that were followed for greater than 6 months.
| Liver biopsy findings
All liver biopsies had histological features of profound intrahepatic cholestasis, without evidence of duct injury or loss. A mild hepatitis was noted without fibrosis, as has been previously reported. 28 The liver histology features noted close to the time of elevated serum aminotransferases were not significantly different from those seen when the R < 5, although there was a trend to an increased presence of hepatocyte apoptosis in the former. As none of the biopsies revealed alternative diagnoses, a liver biopsy may not be necessary when the distinct clinical presentation is evident in a young male and exposure history is consistent.
| Genetic analysis
The prolonged cholestasis with a normal GGT level, when tested, is clinically reminiscent of patients who present with BRIC due to genetic variants in ATP8B1, the P type ATPase responsible for PFIC1 and BRIC-1, or ABCB11, the bile salt export protein responsi- 
| Chemical analysis of bodybuilding supplements
As previously reported, bodybuilding supplement product labels correlated poorly with the chemical analysis, and the steroids species that were found were often not on the label. 35 The presence of anabolic steroids in bodybuilding supplement samples, which are currently listed as controlled substances (https://www.deadiversion.
usdoj.gov/21cfr/cfr/1300/1300_01.htm), illustrates that these DEA controlled steroids are easily available for purchase. Although anabolic steroids were not identified in samples from five patients, not all bodybuilding supplement samples were available for analysis. In addition, the common phenotypic presentation of these patients without anabolic steroids detected in these supplements strongly suggests exposure. Our data are particularly pertinent in the light of the increasing use of anabolic steroids in the adolescent population. A recent survey revealed that up to 1% of adolescent males and 0.1% of adolescent females have been exposed to anabolic steroids in high school with an estimated prevalence of use by 2.9-4 million Americans. 9 Our chemical analysis confirmed identification of controlled steroids, and there was a poor correlation between label and actual content in bodybuilding supplements. These data along with others 35 suggest that greater regulatory oversight is required to protect the general public.
Strengths of our study include the prospective enrollment of consecutive cases, high causality scores and extensive phenotyping including liver biopsies in over 50% of the cases. Available bodybuilding supplement samples were comprehensively analysed, and the chemical structure of the anabolic steroid identified in the vast majority. In this same cohort, genetic variants were sought using either WGS or chip-based discovery, which included known variants in PFIC genes. Weaknesses in our study were the retrieval of bodybuilding supplement agents in only a third of the subjects, inability to demonstrate a clear dose response to liver injury and inadequate follow-up due to poor subject compliance.
In conclusion, patients with liver injury due to bodybuilding sup- 
